The Defense Health Agency awarded a $468,000 Project Grant to the University of California, Los Angeles under the Military Medical Research and Development federal grant program (CFDA 12.420) to support research developing new therapeutic strategies to target TROP2 in aggressive prostate cancer. The two-year award beginning March 15, 2023 will fund research efforts to investigate medical solutions for prostate cancer on the battlefield and transform health care for service members and the public through innovative biomedical research. As the prime awardee, UCLA will leverage its expertise in oncology to conduct the basic, applied, and advanced research outlined under the award in collaboration with its parent institution, the State of California.
Generated 1/6/24, 5:25 PM